FDA grants orphan drug designation to Sanofi's Riliprubart for treating antibody-mediated rejection in transplants.

Sanofi (NASDAQ: SNY) received FDA orphan drug designation for Riliprubart to treat antibody-mediated rejection in organ transplants. The designation benefits Sanofi with tax credits and market exclusivity. Riliprubart is being evaluated in multiple clinical trials for various conditions like kidney transplants and neuropathy. Sanofi focuses on healthcare solutions and research.

Read more at Yahoo Finance: FDA Grants Orphan Drug Designation To Sanofi’s (SNY) Riliprubart